Home Actualité internationale CM – Rexlemestrocel-l from mesoblast reduces cardiovascular mortality, heart attacks / strokes
Actualité internationale

CM – Rexlemestrocel-l from mesoblast reduces cardiovascular mortality, heart attacks / strokes

Mesoblast (MESO) Announces Phase 3 Study Results of Rexlemestrocel-L in 565 New York Heart Association ((NYHA)) Class II and Class III Chronic Heart Failure Patients ...

Keywords:

Mesoblast,Heart failure,ASX,ASX:MSB,Stem-cell therapy,Inpatient care,Stem cell,Cell therapy,Mesoblast, Heart failure, ASX, ASX:MSB, Stem-cell therapy, Inpatient care, Stem cell, Cell therapy,,

[quads id=1]